Vaccine Cold-Chain Pharma MEP — WHO PQS + USP 1079 + IATA TTC + UNICEF CCE

An Indian vaccine manufacturer with 100M-dose annual capacity demands ₹428 Cr cold-chain MEP covering fill-finish ISO 7 environment + -20°C primary + -70°C ultra-cold for mRNA + 2-8°C distribution + refrigerated trucks + regional hubs + 24/7 SOC. WHO PQS + USP 1079 + IATA TTC + UNICEF + EU GDP govern. Three failures: -70°C cell without 2N redundancy + 90-min UPS (₹15-25 Cr product loss per outage), temperature excursion SOP undocumented destroying consignment, dual-chamber truck not validated for -20/2-8°C concurrent.

Vaccine cold-chain pharma framework

Indian vaccine industry (Serum Institute of India, Bharat Biotech, Biological E, Panacea, Cipla, Zydus) supplies 60-70 % of world vaccines. mRNA vaccines require -70°C ultra-cold; conventional EPI vaccines -20°C / 2-8°C. WHO PQS Performance Specifications + USP 1079 (Good Storage + Distribution) + UNICEF Cold Chain Equipment + IATA Time + Temperature Sensitive Label + IS 9989 + GDP (Good Distribution Practice) all govern.

Vaccine cold-chain — 100 million dose annual capacity

Three Indian vaccine cold-chain failures

1. -70°C cell without redundancy + 90-min UPS — mRNA + cell-therapy products at -70°C cannot tolerate > 90 min above -60°C. Specify 2N refrigeration + 90-min UPS + DG auto-start + 24-hr backup tank. Single-system Indian facilities accept ₹15-25 Cr product loss per outage event.
2. Temperature excursion SOP missing — WHO PQS requires documented + tested excursion management — what to do if temp exceeds limit. Most Indian distributors lack documented SOP — single excursion destroys entire consignment with no recovery path.
3. Refrigerated truck without dual-zone validation — concurrent -20°C + 2-8°C in single truck requires partition + dual-chamber validation per WHO + IATA. Indian last-mile uses single-chamber risking thermal interaction + 2-8°C section freezing.